The first matrix metalloproteinase (MMP) was discovered in 1962 from the tail of a tadpole by
its ability to degrade collagen. As their name suggests, matrix metalloproteinases are …

Cancer progression with uncontrolled tumor growth, local invasion, and metastasis depends
largely on the proteolytic activity of numerous matrix metalloproteinases (MMPs), which …

Epidermal growth factor receptor (EGFR) overexpression is common in head and neck
squamous cell carcinoma. Targeted therapy specifically directed towards EGFR has been …

Insulin sensitivity progressively declines with age. Currently, the mechanism underlying age-
associated insulin resistance remains unknown. Here, we identify membrane-bound matrix …

Membrane-type matrix metalloproteases (MT-MMP) are pivotal regulators of cell invasion,
growth and survival. Tethered to the cell membranes by a transmembrane domain or GPI …

For over 20 years, membrane type 1 matrix metalloproteinase (MT1-MMP) has been
recognized as a key component in cancer progression. Initially, the primary roles assigned …

Enhanced invasiveness, a critical determinant of metastasis and poor prognosis, has been
observed in cancer cells that survive cancer therapy, including radiotherapy. Here, we show …

Epithelial-to-mesenchymal transition (EMT) recapitulates metastasis and can be induced in
vitro through transforming growth factor (TGF)-β signaling. A role for MMP activity in …

Bone-resorbing osteoclasts mobilize proteolytic enzymes belonging to the matrix
metalloproteinase (MMP) family to directly degrade type I collagen, the dominant …

Purpose: The extracellular matrix (ECM) is an intriguing, yet understudied component of
therapy resistance. Here, we investigated the role of ECM remodeling by the collagenase …